Eureka Therapeutics announces preclinical results of InvisiMask human antibody nasal spray against SARS-CoV-2 infection
Eureka Therapeutics announced successful preclinical results from its InvisiMask Human Antibody Nasal Spray in mice, which offers protection against SARS-CoV-2 S pseudotyped virus infection for up to 10 hours.